Trials / Completed
CompletedNCT02359344
PK & Tolerability of CNV1014802 in Young and Elderly Healthy Volunteers
A Randomized, Double-blind, Placebo Controlled, Two Period Crossover Study to Investigate the Pharmacokinetics, Tolerability and Cognitive Effects of an Oral Dose Regimen of 150mg Tid CNV1014802 in Healthy Young Versus Elderly Male and Female Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
A randomized, double-blind, placebo controlled, two period crossover study to investigate the pharmacokinetics, tolerability and cognitive effects of 8 days dosing of CNV1014802 in healthy young versus elderly male and female subjects. Treatment periods will be separated by 13 days. The primary outcome measures are pharmacokinetics (PK) and tolerability.
Detailed description
This study was previously posted by Convergence Pharmaceuticals, Ltd., which has been acquired by Biogen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CNV1014802 | |
| DRUG | Placebo |
Timeline
- Start date
- 2015-02-03
- Primary completion
- 2015-04-20
- Completion
- 2015-04-20
- First posted
- 2015-02-10
- Last updated
- 2017-10-12
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02359344. Inclusion in this directory is not an endorsement.